Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.36 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151029 | 0.94 | PIK3CA (0.39) | PIK3CAEGFRAKT1AKT2FGFR4 | |
| SCHEMBL4137710 | 0.85 | PIK3CA (0.40) | PIK3CADYRK1ABRD4EGFRMAP4K1 | |
| SCHEMBL4145055 | 0.84 | CCNE1 (0.44) | — | |
| SCHEMBL3669287 | 0.83 | CCNE1 (0.49) | — | |
| SCHEMBL3673605 | 0.83 | CCNE1 (0.49) | — | |
| SCHEMBL4722727 | 0.83 | CCNE1 (0.49) | — | |
| SCHEMBL4137496 | 0.82 | MAPK14 (0.42) | PIK3CAAKT1MTORTNK2 | |
| SCHEMBL3670875 | 0.81 | CCNE1 (0.47) | — | |
| SCHEMBL3671028 | 0.81 | CCNE1 (0.47) | — | |
| SCHEMBL3679459 | 0.81 | CCNE1 (0.47) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | PIK3CA 473/4885DYRK1A 2814/4885BRD4 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.